Case Study: Building a Greater Asset
Trubion Alliance for the Development and Commercialization of Therapies Utilizing Trubion's Small Modular Immunopharmaceutical (SMIPs) Therapeutics
Partner: Trubion Pharmaceuticals, Inc.
- Global exclusive license announced in January 2006
- Worldwide rights to CD20-Targeted SMIP technology as well as SMIP product candidates from the discovery program. Provides alternative to classic monoclonal antibodies
- The partners are jointly developing compounds for inflammation and oncology indications
- Wyeth contributes its leading process development and manufacturing expertise in biologicals, which helps enable Trubion’s cutting edge science
- Wyeth to exclusively manufacture and commercialize products derived from this alliance
218919-01